ArticleFrontiers in pharmacology2020

Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing.

Chan Gyu Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.